CoChat

Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts

Weber, Karl T · 2004 · Journal of Hypertension
Cited by 93

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Hypertension and heart failure are major health problems of worldwide proportions. Prevention is of paramount importance with efforts focused on the identification and modification of risk, and the presumption of risk reduction favourably influences cardiovascular-related morbidity and mortality. Left ventricular hypertrophy (LVH) is recognized as an important risk factor for adverse cardiovascular events [1–3]. Why should the hypertrophic growth of cardiomyocytes prove detrimental? Athletes have the same left ventricular mass as individuals with mild, moderate and severe hypertension [4]. If it is not the quantity of myocardium that confers increased risk, could it be its quality? The growth of parenchyma (or cardiomyocytes) in hypertensive heart disease (HHD) need not be faulty. Instead, abnormalities of stroma could account for ventricular dysfunction and a predisposition to re-entrant dysrhythmias. An adverse accumulation of fibrous tissue, or fibrosis, is an established morphological feature of HHD whether ventricular tissue is examined postmortem [5–7] or antemortem by endomyocardial biopsy [8]. Morphologically, it presents as a reactive perivascular fibrosis of intramural coronary arteries and arterioles with extensions into the contiguous interstitial space to create an interstitial fibrosis. In response to cardiomyocyte necrosis, a replacement fibrosis, or microscopic scarring, is also seen. What pathophysiological mechanism(s) account for the appearance of fibrous tissue in HHD? Is it simply the longstanding pressure overload? The haemodynamic burden placed on the left ventricle? Numerous studies conducted over the past 30 years have shown that haemodynamic factors govern cardiomyocyte growth while reactive fibrosis is blood pressure independent [9]. Instead, chronic inappropriate (relative to dietary salt) elevations in such circulating hormones as angiotensin II, aldosterone, deoxycorticosterone and endothelin-1 (ET-1) are operative. These same substances are produced de novo within cardiac tissue. Together with fibrogenic cytokines such as transforming growth factor (TGF)-β1 and connective tissue growth factor (CTGF) acting as intermediaries, these signals contribute to stromal growth. How humoral factors and cytokines lead to a fibrogenic cardiac phenotype is an area of ongoing investigation. In the case of primary and secondary aldosteronism, one working paradigm implicates neuroendocrine and immune systems (a neuroendocrine–immune interface) predisposing to an activation of circulating peripheral blood mononuclear cells (PBMC) that subsequently target the intramural vasculature of the heart and systemic organs [10–12]. This immunostimulatory state is induced by iterations in PBMC divalent cation composition (Mg2+ and Ca2+) and is transduced by oxi/nitrosative stress [10, 12–14]. What cells are responsible for the adverse accumulation of connective tissue in HHD? Cardiomyocytes constitute one-third of all cells found in myocardial tissue; the remainder include fibroblasts, endothelial and vascular smooth muscle cells. Fibrous tissue is composed of fibrillar collagens: predominantly type I and to a lesser extent type III collagens [15]. Only fibroblasts have the transcriptome and proteome needed to, respectively, express these fibrillar collagen genes and process the structural proteins. What is known about cardiac fibroblasts? Usual fibroblasts of the normal cardiac interstitium account for the gradual turnover of collagen, a stable structural protein with a half-life of 80–120 days [15]. Studies performed in vivo have addressed the behaviour of fibroblasts involved in a more rapid turnover of collagen that accompanies cardiac remodelling. Various experimental models have been used, including myocardial infarction, pericardial injury, reaction to foreign body (i.e. silk ligature placement), elevations in endogenous effector hormones of the circulating renin–angiotensin– aldosterone system (RAAS) induced by suprarenal aortic or unilateral renal artery banding, and treatment with exogenous angiotensin II, aldosterone or deoxycorticosterone acetate. Fibroblast-like cells responsible for the deposition of fibrillar collagens at sites of repair are phenotypically modified [16]. They are termed myofibroblasts (myoFb) because they express α-smooth muscle actin (α-SMA) microfilaments and therefore are contractile. The source of myoFb is uncertain and may include a pool of circulating fibroblasts, termed fibrocytes, tissue-based fibroblasts, or both [16–18]. Unlike injured skin, where myoFb promote healing and wound closure, and thereafter disappear via apoptosis, myoFb are persistent and active at sites of cardiac fibrosis [19,20]. Whether their prolonged survival is related to suppressed apoptosis remains uncertain. MyoFbs do not operate in isolation. Cell–cell signalling is an integral feature of their behaviour and function. For example, their interplay with invading inflammatory cells leads to fi

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00004872-200401000-00011

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 93

Metadata

Authors
Weber, K. T.
Venue
Journal of Hypertension
Published
2004-01
Volume
22
Issue
1
Pages
47-50
ISSN
0263-6352 (ISSN-L)
OpenAlex
W2073084507
Cited by
93
References
2
FWCI
1.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. https://app.cochat.ai/papers/10.1097/00004872-200401000-00011
The paper
Weber, K. T. (2004). Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. Journal of Hypertension. https://doi.org/10.1097/00004872-200401000-00011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.